Voices
Giuseppe Minniti: Gliofocus Phase 3 Trial Explores PARP Inhibitors with Radiotherapy in GBM

Giuseppe Minniti: Gliofocus Phase 3 Trial Explores PARP Inhibitors with Radiotherapy in GBM

Giuseppe Minniti, Radiation Oncologist at Sapienza University of Rome, shared a post on X by ESTRO, adding:

“The importance of combining PARP inhibitors with radiation therapy is currently being evaluated in Gliofocus phase 3 trial by Ivy Brain Tumor Center testing RT and Niraparib for MGMT unmethylated GBM.”

Quoting ESTRO‘s post:

“Long-term results from the RADIOPARP Phase I Trial: Safety and radiosensitization of Olaparib with radiotherapy in triple-negative breast cancer patients, published in the Red Journal.

Read it before your patients.”

Giuseppe Minniti

Title: Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial

Journal: Red Journal

Authors: Pierre Loap, Delphine Loirat, Marc-Henri Stern, Jean-Yves Pierga, Kim Cao, Anne Vincent-Salomon, Frederique Berger, Alain Fourquet, Youlia Kirova

Read the full article.

Giuseppe Minniti

More posts featuring Giuseppe Minniti on OncoDaily.

Breast Cancer cancer ESTRO GBM Giuseppe Minniti glioblastoma Gliofocus Ivy Brain Tumor Center Niraparib olaparib OncoDaily Oncology PARP inhibitors RADIOPARP radiotherapy Red Journal Sapienza University of Rome triple-negative breast cancer